2 This report focuses on major depression and

its associated symptoms as critical factors and potential modulators of a proposed age-by-disease interaction model. Major depression affects subjects of all ages, increases morbidity in the context of several organ diseases, and overall causes greater disability than all other psychiatric disorders.3 Major depression is a severe mental illness that is defined by specific sets of symptoms, but low mood and anhedonia, the two core symptom dimensions of the illness, are observed across Inhibitors,research,lifescience,medical major mental illnesses and neurodegenerative disorders. Importantly, biological pathways associated with depression overlap with those frequently implicated in aging processes (eg, stress, inflammation, Inhibitors,research,lifescience,medical immune recruitment, and metabolic syndrome), prompting the hypothesis of accelerated aging in depressed subjects:4 Notably, chronic stress, a common precipitating factor in depression, recruits similar pathways and has been suggested as a factor leading to accelerated aging.5 Conversely, while major depression per se does Inhibitors,research,lifescience,medical not increase with older age, a constellation of related symptoms are present in many elderly subjects, even if not categorically diagnosed as depression.2

However, there is also a large variability in individual susceptibility to develop depression and related symptoms with increasing age, and while some dysfunction appears inevitable, Inhibitors,research,lifescience,medical successful emotional, physical, and cognitive aging is achievable. This suggests that agerelated biological mechanisms and functional outcomes, including vulnerability Inhibitors,research,lifescience,medical to experience depressive symptoms, can be slowed down under certain circumstances, and/or that protective mechanisms may be recruited throughout the lifespan. Hence, selleck chem simultaneously investigating the biological causes and reciprocal links between brain aging and neuropsychiatric disorders may provide novel perspectives

on disease mechanisms. Accordingly, since evidence suggests that neural networks and biological mechanisms underlying mood regulation are specifically at risk across disorders and during aging,6 our group has focused on Anacetrapib major depression and aging of the brain, in order to investigate age-by-disease interactions. During our investigations of the molecular bases of major depression in the human post-mortem brain, we have uncovered a large and robust effect of age on multiple genes and biological pathways.7,8 Notably, this set of age-dependent genes broadly overlaps with disease-related pathways, and the changes in gene function observed during aging occur for the most part in directions that would otherwise promote neurological disorders, including depression.